NCT05525520

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Escient Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)

Conditions

• Pruritus

Interventions

Type	Name	Description
DRUG	EP547	Once daily
DRUG	Placebo	Once daily

Timeline

• Start date: 2022-10-06
• Primary completion: 2024-07-17
• Completion: 2024-09-05
• First posted: 2022-09-01
• Last updated: 2025-07-31
• Results posted: 2025-07-31

Locations

52 sites across 8 countries: United States, Belgium, Canada, France, Israel, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study